Matinas BioPharma Holdings, Inc. (6LJ.F)

0,1195 +0,0036 (+3,11%) Börsenschluss: 09:24AM CEST

Matinas BioPharma Holdings, Inc.

1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States
908 484 8805
https://www.matinasbiopharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 32

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jerome D. Jabbour J.D.	Co-Founder, CEO, President & Director	786,67k	N/A	1974
Dr. Theresa Matkovits Ph.D.	Chief Development Officer	532,38k	N/A	1967
Dr. James J. Ferguson FACC, M.D.	Chief Medical Officer	579,93k	N/A	1954
Mr. Keith A. Kucinski CPA, M.B.A.	Chief Financial Officer	232,58k	N/A	1970
Dr. Hui Liu M.B.A., Ph.D.	Chief Technology Officer	N/A	N/A	1968
Mr. Frank Calamusa	Executive Director and Head of Manufacturing & Supply Chain	N/A	N/A	N/A
Mr. Thomas J. Hoover M.B.A.	Chief Business Officer	N/A	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Corporate Governance

Matinas BioPharma Holdings, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.